Peter Ucciferro, DO
Endocrinology, Diabetes & Metabolism · Doylestown, PANPI 1033572318
Payments from drug & device makers
Across 128 payments — averaging $46.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Medtronic$1K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$717
- Amgen$394
- Insulet Corporation$246
- plus $1K from 14 others
What the payments were for
- Food & beverage$5,939100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 17 | $1,428 |
| Medtronic | 16 | $1,108 |
| Novo Nordisk | 23 | $1,042 |
| Sanofi-aventis U.S. LLC | 17 | $717 |
| Amgen(2 entities) | 9 | $394 |
| Insulet Corporation | 6 | $246 |
| Abbott | 8 | $194 |
| Lilly USA, LLC | 8 | $151 |
| Tandem Diabetes Care, Inc. | 5 | $127 |
| Johnson & Johnson | 1 | $125 |
| Shire North American Group Inc | 1 | $70 |
| Radius Health, Inc. | 4 | $68 |
| Sequel Med Tech, LLC | 2 | $52 |
| Neurocrine Biosciences, Inc. | 1 | $40 |
| Mannkind Corporation | 2 | $40 |
| Merck | 3 | $37 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Ascensia Diabetes Care US Inc. | 1 | $34 |
| Tolmar, Inc. | 1 | $20 |
| Intuity Medical Inc | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$1,239
- RYBELSUS$355
- Ozempic$337
- MINIMED 780G$330
- SOLIQUA 100/33$249
- Minimed 630G$161
- MINIMED 770G$141
- EVENITY$125
- INVOKANA$125
- TOUJEO$120
- Minimed 770G System$112
How this compares
$5,946 in reported general payments places this provider in the 70th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 243 | $465,833 |
| MounjaroTirzepatide | 173 | $290,609 |
| TrulicityDulaglutide | 155 | $231,198 |
| JardianceEmpagliflozin | 109 | $137,037 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 17 | $69,234 |
| FarxigaDapagliflozin Propanediol | 54 | $68,972 |
| JanuviaSitagliptin Phosphate | 45 | $42,103 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $36,490 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 221 | $36,083 |
| Novolog FlexpenInsulin Aspart | 122 | $35,066 |
| Humalog Kwikpen U-100Insulin Lispro | 88 | $34,321 |
| Teriparatide | 12 | $29,858 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $29,325 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $27,359 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 18 | $27,055 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $151 | $526,568354 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,042 | $487,450279 claims |
| AstraZenecaFarxiga | $1,428 | $68,97254 claims |
| MerckJanuvia | $37 | $42,10345 claims |
| Sanofi-aventis U.S. LLCLantus | $717 | $3,76530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Doylestown
- Mona Al MukaddamPhiladelphia$3.9M
- Serge JabbourPhiladelphia$3.1M
- Mihaela BiscoveanuPhiladelphia$1.5M
- Barbara SimonPhiladelphia$1M
- Mitchell LazarPhiladelphia$1M
- Vijay BahlPittsburgh$998K
- Intekhab AhmedPhiladelphia$926K
- Erin KershawPittsburgh$804K
- Geraldo SaavedraWhitehall$698K
- Arvind CavaleFeasterville Trevose$662K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.